Myovant Sciences

Myovant Sciences is committed to becoming a leading healthcare company focused on redefining care for women and men. The company’s lead product candidate is relugolix, a once-daily oral GnRH receptor antagonist. Myovant Sciences has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide Kisspeptin-1 receptor agonist, which has completed a Phase 2a study as part of assisted reproduction for the treatment of female infertility.